Increased risk of heart disease was observed after the MRNA covid-19 and highest vaccination in men aged 18-25 years after the second dose of vaccines, a study funded by American health regulators found by the US FDA FDA.
However, it happened “rarely”.
According to research published in the medical journal Peer-Review The Lancet, an increased risk of myocarditis or pericarditis is recorded after MRNA vaccination.
Myocarditis is inflammation of the heart muscle, and pericarditis is inflammation of the outer layer of the heart.
These results do not show statistically significant risk differences between MRNA-1273 (Moderna Vaccine) and BNT162B2 (Pfizer Biontech Vaccine), but should not be set aside that differences may exist, “said research published in the volume of June 11.
Some passive surveillance systems report an increase in the risk of myocarditis or pericarditis, or both, after the MRNA COVID-19 vaccination, especially in young men.
This study uses active supervision from a large health care database to measure and allows the direct comparison of myocarditis or pericarditis risk, or both, after the modern vaccination and pfizer -bonontech.
However, the results of the study, along with the risk profile of benefits, continue to support inoculation using one of two mRNA vaccines.
A total of 411 myocarditis or pericarditis, or both, were observed among 15 million people aged 18-64 years.
Among men aged 18-25 years, the highest level of events collected after the second dose, at 1 · 71 per lakh people for pfizer and 2 · 17 per lakh people for modern.